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ABSTRACT
Objective To evaluate the threshold value of urinary
cadmium (CdU) for renal dysfunction on the basis of
relationships unconfounded by protein degradation,
diuresis and the renal effects associated with chronic
smoking.
Methods We studied 599 workers (451 men, mean age
45.4 years) who were employed in four nickel-cadmium
battery plants for 18.8 years on average. After
adjustment for covariates by multiple regression, the
CdU threshold values for increased concentrations of
retinol-binding protein (RBPU) and b2-microglobulin
(b2-mU) were assessed by logistic regression and
benchmark dose analyses using as referents workers
with CdU<1 mg/g creatinine.
Results Relationships between urinary proteins and CdU
(mg/g creatinine) were inﬂuenced by sex, age, diuresis
and especially smoking. When considering all workers,
odds for abnormal RBPU and b2-mU were signiﬁcantly
increased from CdU of 6-10 and >10, respectively. The
benchmark dose (BMD5) and the benchmark dose lower
limit (BMDL5) for a 5% excess in the background
prevalence of abnormal RBPU and b2-mU were
estimated at 5.1/3.0 and 9.6/5.9. When excluding ever
smokers, odds for abnormal RBPU and b2-mU were both
increased only among workers with CdU>10 (OR, 21.8,
95% CI, 6.4-74.4 and OR, 15.1, 95% CI, 3.6-63.1,
respectively). In never smokers, these BMD5/BMDL5 of
CdU were estimated at 12.6/6.6 and 12.2/5.5 while in
ever smokers they were 6.2/4.9 and 4.3/3.5.
Conclusions On the basis of associations undistorted by
smoking and adjusted for covariates, the BMDL5 of CdU
for low-molecular-weight proteinuria induced by
occupational exposure to Cd can be reliably estimated
between 5.5 and 6.6 mg/g creatinine.
INTRODUCTION
Cadmium (Cd), a by-product of zinc production, is
one of the most toxic metals to which man can be
exposed at work or in the environment.
1 Cd is
primarilytoxictotheproximaltubularcellswhereit
selectively accumulates over time and may cause
irreversible damage. The earliest sign of tubular
dysfunction induced by chronic Cd poisoning is
increasedurinaryexcretionoflow-molecular-weight
(LMW) proteins (molecular weight <40 kD) such as
b2-microglobulin (b2-mU) and retinol-binding
protein (RBPU).
2 Studies conducted in the 1980s on
activeworkersintheCdindustrydemonstratedthat
this LMW proteinuria, also called tubular protein-
uria, is likely to occur in approximately 10% of
workerswhentheCdconcentrationinkidneycortex
exceedsapproximately200 ppm(mg/gwetweightof
renalcortex).
134Thesestudieshavealsoshownthat
beforerenaldysfunctiondevelops,theamountofCd
stored in the kidneys can be assessed non-invasively
bymeasuringtheconcentrationofthemetalinurine
(CdU).
1On thebasis ofthe relationship between Cd
concentrations in the urine and kidney cortex in
workers with no renal dysfunction, the CdU value
corresponding to the critical level of 200 ppm in
kidneycortexwasestimatedat10 mg/gcreatinine,
13
a value in concordance with that derived from
the relationships between b2-mU and CdU.
56The
occupational exposure limit of 5 mg/g creatinine,
which is still in application in most countries, was
set on the basis of this CdU threshold value after
the application of a safety margin of two to account
for inter-individual variations in the renal toxicity of
Cd.
Since then, a number of studies have further
explored the doseeeffect/response relationships for
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What this paper adds
< Studies evaluating the threshold levels of urinary
cadmium (CdU) for increased excretion of low-
molecular-weight proteins have so far regarded
smoking as merely an additional source of
cadmium without taking into account the
detrimental effects of tobacco smoking on the
kidneys.
< This study based on a large cohort of nickel-
cadmium battery plant workers, shows that the
renal effects of chronic smoking substantially
distort the doseeeffect/response relationships
between the urinary excretion of low-molecular-
weight proteins and that of cadmium.
< In never smokers, the CdU threshold values for
abnormal retinol-binding protein and b2-micro-
globulin and their lower CI limits were estimated
at 12.6/6.6 and 12.2/5.5 mg/g creatinine,
respectively.
< In ever smokers, these CdU thresholds were
two to three times lower, reﬂecting the renal
effects of both cadmium and chronic smoking.
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Original articleCd-induced renal dysfunction in industrial workers and in the
general population.
1 7e12 Although utilising the same biomarkers
of exposure and renal effects (mostly CdU and b2-mU), some
studies have derived increasingly lower CdU thresholds.
13e16 (for
review see also Anon
17). Recent studies among children and the
elderly with low-level mixed exposure to elements including Cd
even suggest that Cd can induce LMW proteinuria at CdU<1 mg/
g creatinine, that is at the exposure levels currently prevailing in
industrialised countries.
14 18
Differences in sensitivity between workers and some groups
of the general population, especially the elderly and children,
have been proposed to explain such a wide variation in CdU
thresholds. An alternate explanation, which has received little
consideration even in the most recent risk assessments,
17 might
be insufﬁcient adjustment for potential confounders such as
smoking, ageing and the co-excretion of Cd with urinary
proteins.
11 9In most studies addressing the renal toxicity of Cd,
smoking has been regarded as merely an additional source of
Cd exposure having no other inﬂuence except to increase the Cd
body burden. This long-standing view is now challenged by
studies showing that tobacco smoke is detrimental to renal
function, even in subjects without hypertension or abnormal
glucose metabolism.
20e23 Chronic smoking, even when
moderate, is associated with a marked increase in the urinary
excretion of albumin, which reﬂects glomerular damage linked
most likely to the cardiovascular effects of tobacco smoking.
22 23
This renal damage, although distinct from the tubular
dysfunction caused by Cd, might substantially distort the
doseeresponse relationships between LMW proteins and Cd in
urine. Confounding might arise because of the co-excretion of
Cd with albumin, the main Cd-binding protein in plasma,
24 or
else with LMW proteins since tubulo-interstitial involvement is
common in glomerulopathies.
25 26 In population-based studies
of the elderly, relationships between LMW proteins and Cd in
urine might be further distorted by changes in Cd metabolism
and renal function occurring with advanced age. It is well
established that the renal burden of Cd and thus urinary
excretion of the metal, decrease after the age of 60e70 years,
1
which consequently displaces the doseeeffect/response rela-
tionships to the left with resulting underestimation of the CdU
threshold value. Ageing is also accompanied by abnormalities in
the urinary excretion of albumin and LMW proteins,
27 which
may generate secondary associations because of the co-excretion
of Cd with albumin and/or LMW proteins. Confounding might
also arise from the residual inﬂuence of diuresis, since concen-
trations of Cd and LMW proteins expressed per gram of creati-
nine can still correlate with urinary creatinine.
19 Last, the
proteolytic degradation of b2-m in acidic urine, which starts in
the bladder,
28 is an additional source of confounding that
increases the inter-individual variability of this biomarker and
probably explains why b2-mU is higher in Asian than in
Caucasian populations.
17
The objective of the present study was to carry out a reﬁned
analysis of the doseeeffect/response relationships between
LMW proteins and Cd in the urine of Cd-exposed workers
to determine to what extent renal dysfunction is likely to occur
at CdU levels below the current occupational exposure limit
of 5 mg/g creatinine. We focused our study on active workers
as Cd excretion is reduced after exposure ceases.
29 Different
models were tested to ensure that associations were not
distorted by smoking or diuresis. We also consolidated our
analysis by screening renal dysfunction on the basis of b2-mU
and RBPU, a much more stable biomarker of tubular
dysfunction.
30
MATERIALS AND METHODS
Study population
The studied population comprised 599 active workers employed
in four nickel-cadmium battery plants located in France, Sweden
and the USA. Biological data and information on the duration of
employment and smoking history were obtained in the frame-
work of the workers’ health surveillance programme that was
implemented in each factory in compliance with national
regulations. These data were supplied anonymously by the
factory health care units. The studied database included all
workers examined during 2008e2009 and for whom one
complete set of values for urinary Cd and RBP or b2-m was
available. We excluded one outlier worker who had a normal
CdU value (1.9 mg/g creatinine) but very high concentrations of
RBP and b2-m in urine (>5000 mg/g creatinine). A total of 135
workers had a CdU value above the occupational exposure limit
(5 mg/g creatinine) including 19 workers who had been removed
from Cd exposure. As these workers had CdU levels similar to
those of their colleagues still exposed to Cd (n¼116) (median
(interquartile range, IQR), 8.1 (6.9e9.7) vs 7.5 (6.0e10.3),
p¼0.72), we decided to retain them in the ﬁnal cohort. When
several sets of data were available, we selected the most recent
with a urinary creatinine value close to 1.
Biomarkers
Analyses were performed on untimed urine specimens sent
immediately to our laboratory and kept frozen until protein
analyses. We measured the concentrations of b2-m and RBP by
latex immunoassay with detection and quantiﬁcation limits of
0.5 and 2.5 mg/l, respectively, based on a ﬁvefold dilution of
urine.
31 32 Because of practical constraints, pH could not be
measured in urine samples immediately after collection or in the
laboratory since most samples were buffered by adding 10%
(vol/vol) of a 1 mol/l phosphate buffer pH 7.4. Cd was measured
in urine by means of inductively coupled argon plasma mass
spectrometry with an Agilent 7500 instrument (Agilent Tech-
nologies. Santa Clara, California, USA). Brieﬂy, urine specimens
(500 ml) were diluted quantitatively (1+9) with a HNO3 1%,
HCl 0.5% solution containing Sc, Ge, Rh and Ir as internal
standards. The detection and quantiﬁcation limits were 0.02 and
0.05 mg/l, respectively. Using this method, the laboratory has
obtained successful results in external quality assessment
schemes with a certiﬁcate (2008e2009) awarded by the Institute
for Occupational, Environmental and Social Medicine of the
University of Erlangen, Germany (G-EQUAS programme) and
100% performance (2008e2009) achieved in the PCI and
QMEQUAS programmes organised by the Institut National de
Santé Publique, Québec. Creatinine was determined by a modi-
ﬁed Jaffé reaction using a Beckman Synchron LX 20 analyser
(Beckman Coulter, Krefeld, Germany). This method allows to
minimize interference by protein, bilirubin and glucose.
33 34
Statistics
Concentrations of creatinine, Cd and LMW proteins in urine
were presented as medians with IQRs and normalised by
log-transformation. Age, duration of exposure and number of
pack-years were presented as means with SDs. Associations
between CdU, age and biomarkers of renal function were
assessed by Pearson’s correlation analysis. To analyse the asso-
ciations between these variables and smoking dose (pack-years),
we used the non-parametric Spearman’s rank correlation coef-
ﬁcient. Factors inﬂuencing RBPU and b2-mU were identiﬁed by
stepwise regression analysis by testing as potential predictors
258 Occup Environ Med 2011;68:257e264. doi:10.1136/oem.2009.054122
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as never/ever smoking or as categories of pack-years (never
smoking: 0, low: >1e10, medium: >10e20, and high: >20)
introduced into the models as dummy variables. We also
assessed the interactions of CdU and urinary creatinine with
gender and smoking, as well as the interaction between gender
and smoking. When using the number of pack-years to assess
cumulative exposure to tobacco smoke, current smoking was
added to the list of predictors. Potential predictors were entered
at p<0.25 and retained in the ﬁnal model at p<0.1. When age
and gender did not emerge as predictors at p<0.1, they were
nevertheless forced into the models on the basis of a priori
knowledge. We performed these analyses by testing three
different models to adjust for the residual effect of diuresis. In
a ﬁrst model, we expressed LMW proteins and Cd per gram of
creatinine and excluded urine samples with creatinine values
<0.3 and >3 g/l. In the second model, LMW proteins and CdU
were also expressed per gram of creatinine, but we considered
urinary creatinine as an independent variable. In this model,
CdU was tested after a preliminary adjustment for urinary
creatinine on the basis of the simple regression coefﬁcient in
order to avoid any collinearity and confounding by a residual
inﬂuence of diuresis. In the third model, we expressed the
concentrations of LMW proteins and Cd per litre, considering
urinary creatinine as a separate independent variable as
suggested by Barr et al.
35 Since concentrations of b2-mU below
20 mg/g creatinine usually reﬂect proteolytic degradation due to
pH<5.6,
28 we performed these statistical analyses on all values
of b2-mU and after the exclusion of values <20 mg/g creatinine.
In all these regression models, collinearity was excluded by
calculating the variance inﬂation factor.
To estimate the CdU threshold for renal dysfunction, we
stratiﬁed workers into seven categories of increasing CdU values
(mg/g creatinine): #1, >1e2, >2e3, >3e4, >4e6, >6e10 and
>10. These categories were based on an increment of one unit.
For the most exposed workers, increments of two and four were
used to obtain sufﬁcient number of subjects per category. After
adjustment for their respective covariates, RBPU and b2-mU
were compared between these categories by one-way ANOVA
followed by the TukeyeKramer post hoc test. Risks of increased
urinary RBP and b2-m were then assessed by logistic regression
analysis using as reference level the prevalence of values
exceeding the 95th percentile of urinary concentrations
(adjusted for covariates) among workers with CdU<1 mg/g
creatinine. We used a backward approach by including as
potential predictors the same independent variables as in
multiple regression analyses and removing the least signiﬁcant
predictor until the model contained only variables with p<0.20.
Threshold values of CdU were then estimated by calculating the
benchmark dose (BMD5) and the benchmark dose lower CI limit
(BMDL5) for a 5% excess in the background prevalence of
abnormal RBPU and b2-mU. We used the Hill model as provided
by the software (BMDS v 2.1.1) developed by the US Environ-
mental Protection Agency. The BMD5 corresponds to the lowest
observed adverse effect level (LOAEL) or to the population-based
critical level used in previous studies (a 10% response for
a background prevalence of 5%), while the BMDL5 can be
assimilated to the no observed adverse effect level (NOAEL).
Never/ever smokers across CdU categories were compared using
the c
2 test. The level of statistical signiﬁcance was set at p<0.05.
Statistical analyses were performed by using SAS v 9.1.3.
RESULTS
Table 1 gives the characteristics and biomarker levels of workers
from the four nickel-cadmium battery plants. The population
included 24.7% women and 44.6% ever smokers. Cumulative
exposure to Cd, as reﬂected by CdU, was higher in the French
plants, in particular plant 1 where median CdU was about ﬁve
times higher than the background level in the general popula-
tion. Mean urinary excretion of RBP paralleled CdU, also being
highest in plant 1 in France. Urinary excretion of Cd (mg/g
creatinine) was higher in women than in men (median (IQR)
3.40 (1.16e7.46) vs 1.61 (0.62e3.57), p<0.001) and in ever
smokers compared to never smokers (median (IQR) 2.09
(0.76e4.55) vs 1.67 (0.74e3.91), p¼0.048). Urinary RBP (mg/g
creatinine) was higher in ever than in never smokers (median
Table 1 Characteristics of nickel-cadmium battery workers and biological parameters
France (plant 1) France (plant 2) Sweden USA Total
N 251 221 111 16 599
Women, n (%) 58 (23.1) 49 (22.2) 35 (31.5) 6 (37.5) 148 (24.7)
Age, mean (SD), years 47.8 (6.6) 45.5 (11.3) 40.1 (13.0) 44.9 (7.2) 45.4 (10.3)
Years of exposure, mean (SD) 22.4 (8.1) 18.3 (13.2) 13.7 (10.2) 13.4 (9.7) 18.8 (11.3)
Never smoker, n (%) 154 (61.4) 107 (48.4) 59 (53.2) 12 (75.0) 332 (55.4)
Ex-smokers
n (%) 27 (10.8) 31 (14.0) 24 (21.6) 4 (25.0) 86 (14.3)
Pack-years, mean (SD) 8.3 (7.7) 15.5 (13.7) 11.0 (8.4) 14.9 (8.3) 11.9 (10.7)
Current smokers
n (%) 70 (27.9) 83 (37.6) 28 (25.2) 0 (0) 181 (30.2)
Pack-years, mean (SD) 15.1 (10.2) 16.2 (8.2) 9.3 (9.8) 0 (0) 14.7 (9.5)
Urinary creatinine, median (IQR), g/l 1.37 (0.93e1.80) 1.13 (0.69e1.70) 1.47 (1.08e1.90) 1.53 (1.07e2.15) 1.33 (0.86e1.80)
Urinary Cd, median (IQR)
mg/l 4.72 (2.23e7.84) 1.27 (0.54e2.75) 1.08 (0.49e2.74) 1.48 (0.82e2.73) 2.07 (0.86e5.42)
mg/g creatinine 3.40 (1.74e6.40) 1.24 (0.51e2.81) 0.81 (0.31e1.92) 0.98 (0.73e1.31) 1.82 (0.75e4.11)
Urinary RBP, median (IQR)
mg/l 168 (108e295) 136 (82.0e219) 145 (85.6e215) 117 (64.5e206) 152 (88.5e252)
mg/g creatinine 129 (91.5e194) 119 (80.0e180) 100 (69.0e140) 83.8 (57.0e102) 117 (80.4e176)
Urinary, b2-m*, median (IQR)
mg/l 80.0 (36.0e153) 72.7 (48.2e119) 81.5 (52.0e131) 88.0 (26.0e135) 79.0 (43.0e132)
mg/g creatinine 69.0 (33.9e132) 75.5 (31.7e137) 59.2 (39.5e89.8) 62.5 (9.90e90.1) 66.1 (33.5e122)
*n¼228, 152, 98, 14 for total of 492.
b2-m, concentration of b2-microglobulin; Cd, concentration of cadmium; IQR, interquartile range; RBP, concentration of retinol-binding protein.
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b2-m (mg/g creatinine) was higher in women than in men
(median (IQR) 89.2 (48.4e146) vs 58.6 (31.2e113), p¼0.006).
Smoking history expressed in pack-years was also different
between women and men (mean (SD) 4.8 (7.5) vs 6.6 (10.1),
p¼0.001). It can be seen from table 1 that in relative terms the
inter-individual variability of b2-mU is greater than that of
RBPU, most probably reﬂecting the differences in stability
between the two urinary proteins.
The univariate associations between creatinine, Cd, RBP and
b2-m in urine as well as those with age and pack-years are
shown in table 2. RBPU and b2-mU (all values or only values
>20 mg/g creatinine), expressed per litre or per gram of creati-
nine, were signiﬁcantly correlated with both CdU and number
of pack-years. Of note, the urinary excretion of Cd, RBP and b2-
m expressed per gram of creatinine showed a highly signiﬁcant
negative correlation with urinary creatinine, a residual associa-
tion that persisted after exclusion of extreme values of urinary
creatinine (<0.3 or >3.0 g/l, all p<0.001; results not shown).
Because of this residual inﬂuence of urinary creatinine on the
concentrations of Cd and LMW proteins expressed per gram of
creatinine, we studied factors inﬂuencing the excretion of RBP
and b2-m by testing three models of correction for urinary
creatinine (tables 3 and 4). In the ﬁrst two models, Cd and
proteins were expressed per gram of creatinine. To account for
the residual inﬂuence of diuresis in these two models, we either
eliminated samples with extreme values of creatinine (model 1)
or we considered urinary creatinine as a predictor while further
adjusting CdU for urinary creatinine in order to avoid the
collinearity among predictors shown in table 2 (model 2). In
a third model as proposed by Barr et al,
35 Cd and proteins were
expressed per litre and urinary creatinine was added to the list of
potential predictors. As shown in table 3, whatever the model
selected to adjust for urinary creatinine and for smoking (pack-
years categories or ever vs never smokers), RBPU showed
consistent positive associations with CdU, age, gender (male
sex) and ever smoking or categories of pack-years. For b2-mU, in
contrast, determinants varied depending on the model adopted
(table 4). The urinary excretion of b2-m increased signiﬁcantly
with both CdU and smoking only in the models based on pack-
years categories and on samples with b2-mU >20 mg/g creati-
nine. CdU was the only signiﬁcant predictor emerging in the
other models. The same pattern of associations between LMW
proteins and Cd in urine was found when restricting the analysis
to male workers (results not shown).
Since correction for urinary creatinine is the most commonly
used method to adjust for variation in diuresis in biomonitoring,
we pursued our analysis with the concentrations of LMW
proteins and Cd in urine expressed per gram of creatinine and
adjusted according to model 2 based on pack-years categories.
For b2-mU, we selected the same model 2 but with b2-mU values
>20 mg/g creatinine. We ﬁrst examined whether the associations
between LMW proteins and Cd in urine differed between ever
and never smokers and could be detected at low CdU values or
only above a certain threshold. We found that RBPU and b2-mU
correlated signiﬁcantly with CdU in workers with CdU<2 mg/g
creatinine, and thus in subjects with no or minimal occupational
exposure to Cd. However, as shown in online ﬁgures 1A and B,
these associations were largely driven by smoking as they were
absent in never smokers (RBPU, p¼0.26; b2-mU, p¼0.21), while
they were strengthened among ever smokers (RBPU and b2-mU,
p¼0.02).
Doseeeffect/response relationships were then assessed by
stratifying workers in seven categories of increasing CdU (mg/g
creatinine) using as referents subjects with CdU<1. The 95th
percentile adopted as the upper limit of normal showed little
variation whether calculated on all subjects or on never and ever
smokers separately (RBPU, 256.2, 256.4, 255.5 mg/g creatinine;
b2-mU, 276.4, 266.5, 252.5 mg/g creatinine). Although the
proportions of never/ever smokers did not vary across these CdU
categories both for RBPU (p¼0.67) and b2-mU (p¼0.89), the
doseeeffect relationships were strongly inﬂuenced by smoking
as depicted in online ﬁgure 2. Among never smokers the urinary
excretion of both RBP and b2-m showed a sharp and very
signiﬁcant increase at CdU>10. When considering all workers,
RBPU adjusted for covariates including pack-years increased
signiﬁcantly from CdU>6e10. In ever smokers, RBPU rose
signiﬁcantly again from CdU>10, but no signiﬁcant trend was
seen for b2-mU.
This residual inﬂuence of smoking despite adjustment for
pack-years emerges more noticeably when analysing
doseeresponse relationships between CdU categories (mg/g
creatinine) and the prevalences of increased values of RBPU and
b2-mU. When considering all workers regardless of their
smoking status, the odds for abnormal values of RBPU were
signiﬁcantly increased in subjects with CdU>6e10 (OR 3.9,
95% CI 1.6 to 9.6) as well as in those with CdU>10 (OR 13.3,
95% CI 5.2 to 34.2). The same pattern of increase was observed
with the odds of abnormal b2-mU (CdU>6e10: OR 2.8, 95% CI
0.9 to 8.6; CdU>10: OR 9.4, 95% CI 3.2 to 27.9). The
Table 2 Correlations between studied parameters
Age
Pack-
yearsy
Log CdU
(mg/l)
Log CdU
(mg/g creatinine)
Log CrU
(mg/l)
Log RBPU
(mg/l)
Log RBPU
(mg/g creatinine)
Log b2-mU
(mg/l)
Log b2-mU
(mg/l)>20
Age e
Pack-yearsy 0.10*
Log CdU, mg/l 0.39*** 0.15***
Log CdU, mg/g creatinine 0.52*** 0.18*** 0.88***
Log CrU, mg/l  0.26*** 0.06 0.25***  0.24***
Log RBPU, mg/l 0.01 0.18*** 0.37*** 0.07 0.60***
Log RBPU, mg/g creatinine 0.24*** 0.22*** 0.23*** 0.30***  0.14*** 0.71***
Log b2-mU, mg/l 0.02 0.15** 0.10* 0.07 0.05 0.36*** 0.42***
Log b2-mU, mg/g creatinine 0.14** 0.16***  0.03 0.18***  0.45*** 0.01 0.43*** 0.87***
Log b2-mU>20 mg/l 0.03 0.18*** 0.28*** 0.15** 0.28*** 0.59*** 0.51*** e
Log b2-mU>20 mg/g creatinine 0.21*** 0.19*** 0.10* 0.30***  0.42*** 0.11* 0.55*** e 0.76***
r Values are Pearson’s correlation coefﬁcients.
*p<0.05; **p<0.01; ***p<0.001.
yIndicates Spearman’s rank correlation coefﬁcients with number of pack-years.
b2-mU, concentration of b2-microglobulin in urine; CdU, concentration of cadmium in urine; CrU, concentration of creatinine in urine; RBPU, concentration of retinol-binding protein in urine.
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(BMDL5) for a 5% excess in the background prevalence of
abnormal RBPU and b2-mU were estimated at 5.1/3.0 and 9.6/
5.9. When excluding ever smokers from the analysis, the odds for
abnormal RBPU and b2-mU were signiﬁcantly increased only
among workers with CdU>10 (RBPU: OR 21.8, 95% CI 6.4 to
74.4; b2-mU: OR 15.1, 95% CI 3.6 to 63.1). The BMD5/BMDL5
values for abnormal RBPU and b2-mU in never smokers were
estimated at 12.6/6.6 and 12.2/5.5. Among ever smokers, RBPU
and b2-mU showed a signiﬁcant increase from CdU>6e10
(RBPU: OR 5.8, 95% CI 1.6 to 20.3; b2-mU: OR 5.6, 95% CI 1.3
to 24.6) and CdU>10 (RBPU: OR 5.5, 95% CI 1.23 to 25.0;
b2-mU: OR 5.0, 95% CI 0.9 to 28.5). The BMD5/BMDL5 values
for abnormal RBPU and b2-mU in ever smokers were assessed at
6.3/4.9 and 4.3/3.5, respectively.
If as suggested by our ﬁndings, BMD values are artiﬁcially
decreased by the renal effects of smoking unrelated to Cd, then
in subjects with CdU below the BMDL5 estimated in never
Table 3 Factors inﬂuencing urinary excretion of retinol-binding protein in nickel-cadmium battery workers
Categories of pack-years Never/ever smoking
Independent variables Coefﬁcient (95% CI) Independent variables Coefﬁcient (95% CI)
Model 1
Log RBPU Log CdU (mg/g CrU) 0.142 (0.090 to 0.194) Log CdU (mg/g CrU) 0.143 (0.091 to 0.195)
(mg/g CrU) Age (years) 0.003 (<0.001 to 0.006) Age (years) 0.004 (0.001 to 0.007)
Gender 0.064 (0.005 to 0.122) Gender 0.074 (0.016 to 0.132)
Category of pack-years (medium) 0.075 (0.009 to 0.142) Ever smoking 0.059 (0.010 to 0.107)
Category of pack-years (high) 0.096 (0.006 to 0.186)
Model 2
Log RBPU Log CdU (mg/g CrU) CrU adjusted 0.137 (0.085 to 0.188) Log CdU (mg/g CrU) CrU adjusted 0.138 (0.087 to 0.189)
(mg/g CrU) Log CrU (g/l)  0.180 ( 0.278 to  0.082) Log CrU (g/l)  0.186 ( 0.284 to  0.089)
Age (years) 0.003 ( 0.0001 to 0.005) Age (years) 0.003 (0.001 to 0.006)
Gender 0.097 (0.038 to 0.156) Gender 0.107 (0.049 to 0.166)
Category of pack-years (medium) 0.058 ( 0.007 to 0.122) Ever smoking 0.054 (0.007 to 0.101)
Category of pack-years (high) 0.090 (0.004 to 0.177)
Model 3
Log RBPU Log CdU (mg/l) 0.137 (0.085 to 0.188) Log CdU (mg/l) 0.138 (0.087 to 0.189)
(mg/l) Log CrU (g/l) 0.750 (0.644 to 0.856) Log CrU (g/l) 0.743 (0.638 to 0.849)
Age (years) 0.003 (0.0001 to 0.005) Age (years) 0.003 (0.001 to 0.006)
Gender 0.097 (0.038 to 0.156) Gender 0.107 (0.049 to 0.166)
Category of pack-years (medium) 0.058 ( 0.007 to 0.122) Ever smoking 0.054 (0.007 to 0.101)
Category of pack-years (high) 0.090 (0.004 to 0.177)
Model 1, N¼568; models 2 and 3, N¼599.
Model 1: RBPU and CdU expressed per gram creatinine and exclusion of urine samples with creatinine <0.3 and >3 g/l.
Model 2: RBPU and CdU expressed per gram creatinine but with creatinine tested as an independent variable and CdU further adjusted for creatinine on the basis of the simple regression
coefﬁcient.
Model 3: RBPU and CdU expressed per litre with creatinine tested as an independent variable.
CdU, concentration of cadmium in urine; CrU, concentration of creatinine in urine; RBPU, concentration of retinol-binding protein in urine.
Table 4 Factors inﬂuencing urinary excretion of b2-microglobulin in nickel-cadmium battery workers
Categories of pack-years Never/ever smoking
Independent variables Coefﬁcient (95% CI) Independent variables Coefﬁcient (95% CI)
Model 1
Log b2-mU (mg/g CrU) Log CdU (mg/g CrU) 0.120 (0.022 to 0.218) Log CdU (mg/g CrU) 0.120 (0.022 to 0.219)
Gender  0.101 ( 0.217 to 0.014)
Model 1 with b2-mU>20 mg/g CrU
Log b2-mU (mg/g CrU) Log CdU (mg/g CrU) 0.166 (0.090 to 0.243) Log CdU (mg/g CrU) 0.177 (0.100 to 0.253)
Category of pack-years (high) 0.166 (0.025 to 0.308)
Model 2
Log b2-mU (mg/g CrU) Log CdU (mg/g CrU) CrU adjusted 0.083 ( 0.006 to 0.173) Log CdU (mg/g CrU) CrU adjusted 0.078 ( 0.005 to 0.174)
Log CrU (g/l)  0.937 ( 1.113 to  0.760) Log CrU (g/l)  0.907 ( 1.02 to  0.429)
Model 2 with b2-mU>20 mg/g CrU
Log b2-mU (mg/g CrU) Log CdU (mg/g CrU) CrU adjusted 0.150 (0.078 to 0.222) Log CdU (mg/g CrU) CrU adjusted 0.153 (0.091 to 0.215)
Log CrU (g/l)  0.638 ( 0.777 to  0.498) Log CrU (g/l)  0.614 ( 0.706 to  0.249)
Category of pack-years (high) 0.144 (0.017 to 0.271)
Model 3
Log b2-mU (mg/l) Log CdU (mg/l) 0.083 ( 0.001 to 0.177) Log CdU (mg/g CrU) 0.088 ( 0.001 to 0.177)
Model 3 with b2-mU>20 mg/g CrU
Log b2-mU (mg/l) Log CdU (mg/l) 0.150 (0.078 to 0.222) Log CdU (mg/l) 0.153 (0.091 to 0.215)
Log CrU (g/l) 0.286 (0.135 to 0.436) Log CrU (g/l) 0.308 (0.179 to 0.437)
Category of pack-years (high) 0.144 (0.017 to 0.271)
The models are the same as described in table 3.
For each model, age and gender were forced in the regression.
Model 1, N¼468; model 1 with b2-mU>20 mg/g CrU, N¼393; models 2 and 3, N¼492; models 2 and 3 with b2-mU>20 mg/g CrU, N¼416.
b2-mU, concentration of b2-microglobulin in urine; CdU, concentration of cadmium in urine; CrU, concentration of creatinine in urine.
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Original articlesmokers, the excretion of RBPU and b2-mU adjusted for cova-
riates including CdU should increase with categories of pack-
years. We checked the validity of this assumption by performing
the same analyses as above but only among subjects with
CdU<BMDL5 (6.6 mg/g creatinine). Table 5 shows that in men
the risk of increased RBPU and the mean concentration of b2-m
rose dose dependently across categories of pack-years. Of note,
the workers who had smoked moderately (10e20 pack-years)
were three times more likely to have increased excretion of
RBPU (OR 3.11, 95% CI 1.28 to 7.55) while being the same age
and having the same CdU as never smokers. Such associations
were not found in women (all p>0.17; data not shown).
DISCUSSION
The primary goal of this study was to re-assess the threshold
value of urinary Cd for renal dysfunction by taking into account
confounders that might explain the discordant results between
studies involving industrial workers and those based on the
general population. Potential confounders tested in our study
included age, gender, smoking and the residual inﬂuence of
diuresis after correction for urinary creatinine. We also took into
account the bias that might result from the instability of urinary
b2-m by using RBPU, a much more stable biomarker, as well as
by excluding urine samples with abnormally low values of b2-mU.
Our results show that chronic smoking causes a shift in the
doseeeffect/response relationship, which leads to a signiﬁcant
underestimation of the CdU threshold value. The BMD5 values
of CdU for increased b2-mU and RBPU derived in never smokers
(w12 mg/g creatinine) were two or three times higher than those
calculated among ever smokers. Such differences persisted in the
whole population despite adjustment of urinary LMW proteins
for smoking status or pack-years smoking history, which means
that a reliable evaluation of the BMD can be performed only by
excluding ever smokers from the analysis.
Confounding of the associations between LMW proteins and
Cd in urine appears to stem primarily from the renal damage
associated with chronic smoking.
20e23 Cumulative exposure to
tobacco smoke evaluated on the basis of pack-years was posi-
tively associated with urinary excretion of both RBP and b2-m.
Interestingly, this tubular dysfunction associated with smoking
emerged in men but not in women, a phenomenon also
described by Briganti et al
22 and Orth et al.
36
The exact mechanism by which tobacco smoking causes renal
damageanddistortstherelationshipsbetweenLMWproteinsand
Cd in urine is unknown. Our ﬁndings suggest that the LMW
proteinuria associated with chronic smoking is unlikely to be
caused by Cd alone. In multivariate analyses, the associations of
RBPU and b2-mU with pack-years history emerge concurrently
with the association of these proteins with CdU, which however
integrates exposure to Cd from all sources, including tobacco
smoke. The fact that cumulative smoking is associated with
LMW proteinuria only in men also argues against Cd being the
sole causative agent since there is no evidence that men are more
sensitivetoCdthanwomen.
1Astotheshiftofthedoseeresponse
relationships to lower CdU values observed in ever smokers, we
think that it might result from two distinct, although not
exclusive, mechanisms. One mechanism might be an effect
modiﬁcation similar to that proposed for the Cdediabetes inter-
action reported previously.
18According to this mechanism, the
renal impairment associated with smoking would make the
kidney more sensitive to Cd toxicity, thereby decreasing the CdU
threshold. The second mechanism might be a distortion of the
doseeresponse curve by secondary associations linked to the
toxicokineticsofCd.Forinstance,anassociationbetweenurinary
Cdandrenaldysfunctioninsmokersmightdevelopsecondarilyto
the accumulation and progressive rise in urinary Cd that occurs
during chronic smoking. Another possibility directly involving
the glomerular damage
22 23 associated with chronic smoking
would be enhanced co-excretion of Cd with albumin, the main
Cd-binding protein in plasma.
24 A third possibility would be
increased co-excretion of Cd with LMW proteins, in particular
with metallothionein, which has been shown to follow the same
glomerular ﬁltrationetubular reabsorption pathway as other
LMW proteins.
37 The increased excretion of metallothionein
following tubular damage is a well-known phenomenon which
has been demonstrated in experimental animals.
38 The decreased
renal uptake of proteins in subjects with glomerular proteinuria
might be the consequence of tubular damage, but it might also
simply result from competitive inhibition oftubular reabsorption
of LMW proteins by the high ﬁltered load of albumin and other
highmolecularweightproteins.
39Inthisthirdmechanism,which
Table 5 Risks of low-molecular-weight proteinuria in male workers with CdU<BMDL5 (6.6 mg/g creatinine) according to cumulative smoking
Categories of pack-years
Never smokers <10 10e20 >20 p Value
N* 232 61 69 39
Age, mean (SD), years 44.0 (10.0) 40.1 (8.8) 42.0 (10.7) 52.5 (6.7)x <0.001
Cd in urine
Median (IQR), mg/g creatinine adjusted
for CrU
1.40 (0.57e2.90) 1.23 (0.55e2.75) 1.15 (0.52e3.08) 2.63 (1.52e3.76)x 0.004
RBP in urine adjusted for age, CrU and CdUy
Median (IQR), mg/g creatinine 113 (78e160) 135 (99.8e178) 143 (96.7e200)x 141 (86e205) 0.03
N>285 mg/g creatinine (%) 12 (5.2) 3 (4.9) 10 (14.5) 4 (10.3) 0.03
OR (95% CI) 1.00 (1.0 to 1.0) 0.95 (0.26 to 3.47) 3.11 (1.28 to 7.55) 2.10 (0.64 to 6.86)
b2-Microglobulin in urine adjusted for CrU and CdUy, z
Median (IQR), mg/g creatinine 78.7 (54.5e120) 77.0 (55.2e144) 92.7 (62.3e149) 121 (80.7e231)x 0.02
N>295 mg/g creatinine (%) 8 (5.1) 3 (7.0) 3 (5.9) 2 (7.7) 0.59
OR (95% CI) 1.0 (1.0 to 1.0) 1.41 (0.36 to 5.55) 1.17 (0.30 to 4.60) 3.41 (0.31 to 7.81)
p Values indicate the level of statistical signiﬁcance in the c
2 test for trend (prevalences) or in one-way ANOVA.
*For b2-mU, n¼158, 43, 51 and 26.
yAdjustment based on the multiple regression analysis of data in workers with CdU<6.6 mg/g creatinine.
zb2-mU>20 mg/g CrU.
xDenotes statistical signiﬁcance (p<0.05) by comparison with never smokers (Tukey-Kramer post hoc test).
b2-mU, concentration of b2-microglobulin in urine; BMDL5, benchmark dose lower limit for a 5% excess in the background prevalence of abnormal RBPU and b2-mU; CdU, urinary cadmium;
RBPU, retinol-binding protein.
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Original articlemight apply to situations other than smoking, CdU would thus
be a reﬂection more of the functional integrity of the proximal
tubule than of the Cd body burden. We are currently exploring
these different mechanisms by assessing the impact of high
albumin excretion on the relationships between LMW proteins
and Cd in urine from Cd-exposed workers and from populations
with low environmental exposure to Cd.
40
Smoking, although having a very signiﬁcant inﬂuence, is not
the only factor that may bias risk assessment of Cd. As shown in
our study, excretion of both Cd and LMW proteins is still
inﬂuenced by diuresis after correction for urinary creatinine. In
addition to interacting positively with smoking to increase the
excretion of LMW proteins in urine, gender appears to have an
independent inﬂuence on the excretion of RBP, which was
slightly higher in men than in women. We found, however, no
evidence of an interaction between gender and CdU regarding
the risk of LMW proteinuria, suggesting that men and women
present the same sensitivity to the nephrotoxic effects of Cd.
Other potential sources of confounding, which were not really
relevant to the present study, include ageing and the decrease in
Cd body burden after removal from exposure.
The strength of our study lies mainly in the fact that it has
been performed under conditions which do not require the use of
uncertainty or adjustment factors for setting occupational
exposure limits in contrast to risk assessments based on aggre-
gate or extrapolated data.
17 Since our study involved only active
workers, adjustment for the loss of Cd occurring after retirement
was not necessary.
29 The studied cohort was also sufﬁciently
large to allow estimation of threshold values for Cd-induced
LMW proteinuria using data from never smokers only, which
seems to be the most reliable way to derive associations
unconfounded by smoking. The use of RBPU and b2-mU which
we measured by means of very sensitive assays, represents
another strength in comparison with those studies which
measured only one LMW protein, most frequently b2-mU,
a protein unstable in acid urine or else protein HC, a more stable
but less speciﬁc indicator of tubular dysfunction.
Our study, however, has some limitations. Since data were
collected in the framework of medical surveillance in the
workplace, we did not have access to workers’ complete medical
ﬁles, so some information on disease likely to affect renal
function or to modify the renal response to Cd could not be
retrieved (eg, hypertension, diabetes, urinary tract infection,
etc). Nor did we collect data on alcohol consumption, physical
activity and possible exposure to other nephrotoxicants at
home. Concentrations of albumin or total protein in urine were
not available for all participants, which would have permitted
direct adjustment for the glomerular damage caused by smoking
or other chronic diseases unrelated to Cd.
In conclusion, our study provides evidence that BMD values
derived from populations including smokers do not represent the
truethresholdfortherenaldysfunctioninducedbyCdevenwhen
data are adjusted for smoking status or cumulative exposure to
tobacco smoke. Because of the renal effects of smoking unrelated
to Cd, doseeeffect/response relationships between LMW
proteins and Cd in urine are shifted to lower CdU values. When
doseeeffect/response relationships are not distorted by the renal
toxicity of tobacco smoke and adjusted for age, sex and the
residual inﬂuence of diuresis, the BMDL5 values of CdU for LMW
proteinuria induced by occupational exposure to Cd can be reli-
ably estimated between 5.5 and 6.6 mg/g creatinine. The corre-
sponding BMD5 values are estimated around 12 mg/g creatinine,
which is in agreement with the critical concentration of 10 mg/g
creatinine derived in earlier studies.
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